Autoimmune Hemolytic Anemia

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-08-01
EMA Authorised: Enjaymo (sutimlimab) — Recordati Rare Diseases
EMA authorised Enjaymo (sutimlimab) for the treatment of cold agglutinin disease (autoimmune hemolytic anemia), with orphan medicine designa…